Guided Therapeutics (GTHP) Total Non-Current Liabilities (2013 - 2025)
Guided Therapeutics (GTHP) reported Total Non-Current Liabilities of $694000.0 for Q4 2025, up 519.64% on a YoY basis from $112000.0 in Q4 2024, and up 778.48% sequentially from $79000.0 in Q3 2025.
Guided Therapeutics (GTHP) Total Non-Current Liabilities (2013 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 13 years of Total Non-Current Liabilities data on file, last reported at $694000.0 in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 519.64% year-over-year to $694000.0; the trailing twelve-month figure through Dec 2025 stood at $694000.0 (up 519.64% YoY), and the FY2025 full-year result was $694000.0, up 519.64% from the prior year.
- Total Non-Current Liabilities advanced to $694000.0 in Q4 2025, from $79000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 million in Q4 2021 to a low of $35000.0 in Q2 2025.
- A 5-year average of $870950.0 and a median of $710500.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities slumped 90.6% in 2024 and soared 519.64% in 2025, its largest moves.
- Tracing GTHP's Total Non-Current Liabilities over 5 years: stood at $1.8 million in 2021, then fell by 22.95% to $1.4 million in 2022, then plunged by 51.74% to $666000.0 in 2023, then slumped by 83.18% to $112000.0 in 2024, then soared by 519.64% to $694000.0 in 2025.
- Business Quant data shows GTHP's Total Non-Current Liabilities at $694000.0 in Q4 2025, $79000.0 in Q3 2025, and $35000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 694,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 694,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 96,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Sep 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Dec 31, 2023 | 666,000.00 |
| Sep 30, 2023 | 693,000.00 |
| Jun 30, 2023 | 727,000.00 |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.27 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 1.79 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.72 Mn |
| Mar 31, 2021 | 1.07 Mn |